REPL (Replimune Corp) Utang jangka dawa

Replimune Group, Inc. (REPL) is advancing cancer immunotherapy through strategic alliances with pharma behemoths and mergers. The quote characteristic (separate_debt_long) stands at 0.12. Innovation centers in the UK and US are developing melanoma treatments in collaboration with clinics. Share price growth is expected following the completion of final trials and the FDA application, while investors have already priced in current expenditures.

REPL (Replimune Corp) riwayat Utang jangka dawa perusahaan saka 04.07.2022 nganti 28.10.2026

Rincian metrik keuangan lan pasar Replimune Corp (REPL)

- rega lan prakiraan konsensus rega:

Kutipan saham replimune.com|REPL - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Replimune|REPL - Nilai Total Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Replimune|REPL - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku replimune.com|REPL - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Utang marang Modal Replimune Group, Inc.|REPL - Rasio utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal Replimune Inc.|REPL - Gunggung utang perusahaan|Rasio utang marang aset resik Replimune|REPL - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Replimune

Analisis komprehensif perusahaan:REPL (replimune.com)

This indicator tracks the volume of obligations with a maturity of more than one year, reflecting the long-term financing strategy and the credit load of the business. For Replimune Group, Inc. (REPL), such funds are critical for diversifying the clinical trials of the RP1 platform and mitigating regulatory risks. Analyzing the company's long-term debt structure allows for an assessment of the balance between leveraged capital and investment potential. The stability of this metric confirms the fundamental resilience of the biotech.

Perusahaan pesaing